Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...
Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of ...
Discover investment opportunities in lesser-covered stocks like Arcus Biosciences, Sarepta Therapeutics, and Edison ...
A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...
2d
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on SRPT stock, giving a Buy rating yesterday.Stay Ahead of the ...
The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...
2d
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price ...
Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...
An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, ...
Mike Morin: We’re very proud to represent Sarepta Therapeutics, an innovative biotechnology company that focuses exclusively ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback